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A B S T R A C T
Background
Formoterol is a long-acting beta2-agonist but because it has a fast onset of action it can also be used as a relief medication.
Objectives
To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting beta2-agonists in adults and children
with asthma.
Search methods
We searched the Cochrane Airways Group Specialised Register and websites of clinical trial registers (for unpublished trial data), and
we checked the Food and Drug Administration (FDA) submissions in relation to formoterol. The date of the most recent search was
February 2010.
Selection criteria
Randomised, parallel-arm trials of at least 12 weeks duration in patients of any age and severity of asthma. Studies randomised patients
to any dose of as-needed formoterol versus short-acting beta2-agonist. Concomitant use of inhaled corticosteroids or other maintenance
medication was allowed, as long as this was not part of the randomised treatment regimen.
Data collection and analysis
Two authors independently selected trials for inclusion in the review. Outcome data were extracted by one author and checked by the
second author. We sought unpublished data on primary outcomes.
Main results
This review includes eight studies conducted in 22,604 participants (mostly adults). Six studies compared formoterol as-needed to
terbutaline whilst two studies compared formoterol with salbutamol as-needed. Background maintenance therapy varied across the
trials. Asthma exacerbations and serious adverse events showed a direction of treatment effect favouring formoterol, of which one
outcome reached statistical significance (exacerbations requiring a course of oral corticosteroids). In patients on short-acting beta2-
agonists, 117 people out of 1000 had exacerbations requiring oral corticosteroids over 30 weeks, compared to 101 (95% CI 93 to 108)
out of 1000 for patients on formoterol as-needed. In patients on maintenance inhaled corticosteroids there were also significantly fewer
exacerbations requiring a course of oral corticosteroids on formoterol as-needed (Peto OR 0.75; 95% CI 0.62 to 0.91). There was one
death per 1000 people on formoterol or on short-acting beta2-agonists.
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Authors’ conclusions
In adults, formoterol was similar to short-acting beta2-agonists when used as a reliever, and showed a reduction in the number of
exacerbations requiring a course of oral corticosteroids. Clinicians should weigh the relatively modest benefits of formoterol as-needed
against the benefits of single inhaler therapy and the potential danger of long-term use of long-acting beta2-agonists in some patients.
We did not find evidence to recommend changes to guidelines that suggest that long-acting beta2-agonists should be given only to
patients already taking inhaled corticosteroids.
There was insufficient information reported from children in the included trials to come to any conclusion on the safety or efficacy of
formoterol as relief medication for children with asthma.
P L A I N L A N G U A G E S U M M A R Y
Formoterol versus short-acting beta-agonists as symptom relief for adults and children with asthma
Short-acting beta-agonists are traditionally used to ease symptoms when people experience wheezing and breathlessness during asthma
exacerbations. Formoterol is a bronchodilator that works quickly to relieve symptoms and the effect lasts longer. We are interested
in whether there are any benefits or disadvantages associated with using formoterol instead of more traditional treatments to relieve
symptoms.
We found eight trials involving a total of 22,604 patients. We found that taking formoterol reduced the risk of having an exacerbation
that was treated with oral corticosteroids, but none of the other benefits from taking formoterol were statistically significant. Guidelines
suggest that long-acting beta-agonists should be given only to patients already taking an inhaled corticosteroid.
We could not find enough trials conducted in children to reach a conclusion on the benefits and harms in children, so we do not
recommend using the results to make recommendations on treatment of children with asthma.
2Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Formoterol versus short-acting beta2-agonist as relief medication for asthma
Patient or population: Patients with asthma
Settings: International studies
Intervention: Formoterol versus short-acting beta2-agonist
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Formoterol versus short-
acting beta2-agonist
Patients with an exac-
erbation requiring hospi-
talisation
Follow up: mean 30
weeks
16 per 10001 13 per 1000
(11 to 17)
OR 0.84
(0.67 to 1.04)
22236
(7 studies)
⊕⊕⊕©
moderate2
Patients with an ex-
acerbation requiring a
course of oral corticos-
teroids
Follow up: mean 30
weeks
117 per 10001 101 per 1000
(93 to 108)
OR 0.84
(0.77 to 0.91)
21591
(6 studies)
⊕⊕⊕©
moderate3
Exacerbations
were still significantly re-
duced when results were
confined to double-blind
studies
Fatal serious adverse
events (all-cause)
Follow up: mean 30
weeks
1 per 10001 1 per 1000
(1 to 2)
OR 1.08
(0.51 to 2.3)
21629
(5 studies)
⊕⊕©©
low4
There were few deaths
in participants on either
medication. A larger trial
is unlikely to be powered
to detect a difference in
mortality
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Patients with a seri-
ous adverse event (all
cause)
Follow-up: mean 30
weeks
35 per 10001 33 per 1000
(29 to 38)
OR 0.94
(0.81 to 1.08)
22538
(7 studies)
⊕⊕©©
low2,3
Patients with a serious
adverse event (asthma
related)
Follow up: mean 30
weeks
14 per 10001 13 per 1000
(10 to 16)
OR 0.91
(0.72 to 1.15)
21986
(6 studies)
⊕⊕©©
low2,3
Withdrawals (any rea-
son)
Follow up: mean 30
weeks
72 per 10001 80 per 1000
(73 to 87)
OR 1.12
(1.02 to 1.24)
22541
(7 studies)
⊕⊕©©
low3,5
Confining the analysis
to double-blind studies
changed the direction of
the treatment effect
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Mean control event rate.
2 Confidence interval includes the possibility of benefit or harm.
3 One study was open-label.
4 Few participants died which led to wide confidence intervals.
5 There was significant heterogeneity in this outcome, probably due to the open-label design and population-wide nature of RELIEF.
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B A C K G R O U N D
Description of the condition
There is currently no universally accepted definition of the term
asthma. This is in part due to an overlap of symptoms with other
diseases such as chronic bronchitis but is also due to the probable
existence of more than one underlying pathophysiological process.
There are, for example, wide variations in the age of onset, symp-
toms, triggers, association with allergic disease and the type of in-
flammatory cell infiltrate seen in patients diagnosed with asthma
(Miranda 2003). Patients with all forms and severity of disease
will typically have intermittent symptoms of cough, wheeze and/
or breathlessness. Underlying these symptoms there is a process
of variable, at least partially reversible, airway obstruction, airway
hyper-responsiveness and chronic inflammation.
Description of the intervention
People with persistent asthma can use preventer therapy (usually
low-dose inhaled corticosteroid (ICS)) to maintain symptom con-
trol, improve lung function and reduce emergency care require-
ment (Adams 2008). However, when symptoms deteriorate, re-
liever medication in the form of short-acting beta2-agonists such
as salbutamol or terbutaline (BTS/SIGN 2008) is required. An
alternative long-acting beta2-agonist (LABA), formoterol, has the
potential to be used as reliever therapy, as it has an onset of action
that is as fast as salbutamol and terbutaline, unlike another long-
acting beta2-agonist, salmeterol (Palmqvist 2001).
How the intervention might work
Formoterol can be used to relieve bronchospasm and may have
advantages over using salbutamol and terbutaline as reliever med-
ication, since the benefit lasts for 12 hours (Lötvall 2008). Con-
cerns have been raised about the use of regular salmeterol and for-
moterol in asthma, in particular where it is used without a regular
inhaled corticosteroid, in relation to the possible increased risk of
severe adverse events and asthma-related death (Cates 2008; Cates
2008a; Walters 2007).
Why it is important to do this review
The only largeworldwide safety study on formoterol has beendone
on its use as relief medication (RELIEF 2003). This trial was not
considered in a previous systematic review which evaluated the use
of regular formoterol compared to placebo (Cates 2008a) rather
than as a relief medication; the review showed that there was an
increased risk of serious adverse events in patients on maintenance
formoterol. Although the use of single inhaler therapy has been
advocated as a new approach to asthma care (Barnes 2007), and as
way of increasing compliance with inhaled corticosteroids (Delea
2008; Sovani 2008), others have pointed out limitations in the
current research evidence on formoterol alone in children and
adults with less severe asthma (Bisgaard 2003; Lipworth 2007).
Although there are existing reviews on formoterol combined with
an inhaled corticosteroid used formaintenance and relief of asthma
symptoms (Cates 2009; Cates 2009a), there is currently no sys-
tematic review of the efficacy and safety of formoterol alone as
reliever therapy.
O B J E C T I V E S
To assess the efficacy and safety of formoterol as reliever therapy
in asthma in comparison to short-acting beta2-agonists for relief
of symptoms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials of parallel-group design of at least 12 weeks
duration were included in the review. Open-label and double-
blind study designs were eligible. We excluded cross-over trials.
Types of participants
Adults and children with a diagnosis of asthma. We accepted trial-
ist-defined asthma and recordedboth the definitionof asthmaused
in the studies and the entry criteria. Studies on patients with acute
asthma or exercise-induced bronchospasm were not included.
Types of interventions
Eligible treatment group intervention
Studies which assessed the effects of using any dose of formoterol
for the relief of asthma symptomswere eligible.Othermaintenance
treatments were allowed provided they were not part of the as-
needed randomisation regime.
Eligible control group treatment
The control groups for the studies in this review consisted of short-
acting beta2-agonists (salbutamol or terbutaline) for relief of symp-
toms. Studies that compared different doses of formoterol, or dif-
ferent delivery devices or propellants were not included.
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Types of outcome measures
Primary outcomes
1. Patients with exacerbations requiring hospitalisation
2. Patients with exacerbations requiring oral corticosteroids
3. Fatal serious adverse events (all-cause)
4. Non-fatal serious adverse events (all-cause and asthma-
related)
Secondary outcomes
1. Diary card morning and evening peak expiratory flow (PEF)
2. Clinic spirometry (FEV1)
3. Symptoms/symptom-free days
4. Nocturnal awakenings
5. Quality of life
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals andmeeting abstracts (please see the Airways Group
Module for further details). All records in the Specialised Register
coded as ’asthma’ were searched using the following terms:
(formoterol or eformoterol or oxis or foradil) and (relie* or “as
need*” or as-need* or prn)
Searching other resources
We contacted the manufacturer in order to confirm data
and to establish whether other unpublished or ongoing stud-
ies are available for assessment. We handsearched clinical trial
websites (www.clinicalstudyresults.org; www.clinicaltrials.gov;
www.fda.gov) and the clinical trial websites of the manufacturer
of formoterol (www.astrazenecaclinicaltrials.com).
Data collection and analysis
Selection of studies
Following electronic literature searches, two review authors (CC
and EJW) independently selected articles on the basis of title and/
or abstract for full-text scrutiny.We agreed a list of articles to be re-
trieved and subsequently assessed each study to determine whether
it was a secondary publication of a primary study publication and
whether the study met the entry criteria of the review.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
1. Design (description of randomisation, blinding, number of
study centres and location, number of study withdrawals).
2. Participants (N, mean age, age range of the study, baseline
lung function, % on maintenance ICS or ICS/LABA
combination and average daily dose of steroid (beclomethasone
dipropionate equivalent), entry criteria).
3. Intervention (type and dose of component ICS and LABA,
control limb dosing schedule, intervention limb dose adjustment
schedule, inhaler device, study duration and run-in)
4. Outcomes (type of outcome analysis, outcomes analysed).
Assessment of risk of bias in included studies
We assessed the risk of bias in the included studies as either high,
low or unclear using the Cochrane Collaboration’s ’Risk of bias’
tool (Higgins 2008) and the following headings 1) sequence gener-
ation; 2) allocation concealment; 3) blinding; 4) incomplete out-
come data; 5) selective outcome reporting; and 6) other bias.
Measures of treatment effect
We extracted data, where possible, for each of the outcomes listed
above from the trial publication(s) and contacted trialists andman-
ufacturers for further information. We entered exacerbations into
the meta-analysis by subtype (hospitalisation and courses of oral
steroids), rather than as a composite outcome and figures were cal-
culated from other outcome data and verified by the manufacturer
where necessary. We considered serious adverse events separately
as fatal and non-fatal events.
Unit of analysis issues
We used or requested data from the trial sponsors that were re-
ported with patients (rather than events) as the unit of analysis
for the primary outcomes. Some patients suffer more than one
exacerbation over the course of a study and these events are not
independent. Where it was not possible to obtain these data, we
entered events and discussed any effects this may have on the re-
sults of individual meta-analyses.
Dealing with missing data
The proportion of randomised patients who provided data for the
main outcomes was reported and compared with the number of
patients with events in each outcome category.
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Assessment of heterogeneity
We measured statistical variation between combined studies by
the I2 statistic (Higgins 2003). We investigated possible causes of
any heterogeneity that were found.
Assessment of reporting biases
We inspected funnel plots to see if there was evidence of publica-
tion bias where there were enough studies to render this meaning-
ful. Where possible we compared the outcomes suggested in the
trial protocol with those reported for each trial.
Data synthesis
We combined data with Review Manager 5 (RevMan 2008) using
a fixed-effect mean difference (calculated as a weighted mean dif-
ference) for continuous data variables, and a fixed-effect odds ratio
for dichotomous variables. For the primary outcomes of exacer-
bations and serious adverse events we calculated a number needed
to treat (NNT) (benefit or harm) for the different levels of risk
as represented by control group event rates over a specified time
period using the pooled odds ratio and its confidence interval us-
ing an on-line calculator, Visual Rx. The Peto odds ratio was used
for subgroup analysis as there were no important differences in
the results when compared to the Mantel-Haenszel odds ratio and
Peto allows for a test of subgroup interaction to be calculated in
Review Manager 5.
We constructed ’Summary of findings’ tables for the four primary
outcomes.
Subgroup analysis and investigation of heterogeneity
We intended to pool data from adults and children separately and
requested separate information on outcomes in order to compare
adults and children using subgroup analysis, but it was not possible
to obtain separate results on children from the trials that included
adults and children. We also intended to perform subgroup analy-
ses based on use of maintenance inhaled corticosteroids and long-
acting beta2-agonists, and asthma severity.
Sensitivity analysis
We conducted sensitivity analyses on the basis of risk of bias in
studies and methods of data analysis (OR, RR, RD with fixed and
random-effects models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We conducted an all-years search of the Airways Group Register
in February 2010. There was no restriction on language of the
search. The search yielded a total of 140 references. We examined
the reference list of titles and abstracts and assessed each reference
against eligibility criteria. We retrieved full text articles of 35 ref-
erences. We identified 8 included studies and 6 excluded studies
and complete agreement was reached between authors. A search of
www.astrazenecaclinicaltrials.com yielded five study reports corre-
sponding to five of the included clinical trials and an AstraZeneca
Briefing Document was found on the FDA website. We asked As-
traZeneca if there were any additional study reports or references
to studies that they had sponsored, but none were returned.
Included studies
Full details can be found in the Characteristics of included studies
tables.
Participants
A total of 22,604 participants were randomised to eight eligible
studies (Ind 2002; Jain 2004; Rabe 2006; RELIEF 2003; SD-037-
0714; SD-037-0716; Tattersfield 2001; Villa 2002). The largest
trial wasRELIEF 2003with 17,862participants, whilst Rabe 2006
had 2281 participants and the remaining six trials had between
60 and 675 participants. The trials were also of different lengths
with a mean duration of 29.5 weeks; three trials were 12 months
long (Rabe 2006; SD-037-0714; SD-037-0716), three were six
months long (Jain 2004; RELIEF 2003; Villa 2002) and two were
three months long (Ind 2002; Tattersfield 2001).
Two trials (Ind 2002; Tattersfield 2001) were conducted in adults,
one in children (Villa 2002), four trials (Rabe 2006;RELIEF2003;
SD-037-0714; SD-037-0716) were conducted in adults and chil-
dren and it was unclear in what population Jain 2004 was con-
ducted. Participants with a range of different asthma severities
across studies were enrolled. The largest study (RELIEF 2003) al-
lowed any severity of asthma, whilst Rabe 2006 allowed moderate
to severe, Tattersfield 2001 andVilla 2002 allowedmild-moderate,
SD-037-0714 participants had mild asthma and SD-037-0716
had intermittent asthma.
Interventions
All eight trials compared formoterol as-needed with one of two
short-acting beta2-agonists (Table 1) and most were designed to
show that formoterol was as safe as the short-acting beta2-agonist
in question. Formoterol was compared with terbutaline in six trials
(Ind 2002; Rabe 2006; SD-037-0714; SD-037-0716; Tattersfield
2001; Villa 2002) and salbutamol in two trials (Jain 2004; RELIEF
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2003). In addition to the as-needed medications, participants in
some trial were permitted to take, or required to be on, additional
maintenance medication (Table 1). Although this review addresses
formoterol used as-needed rather than asmaintenance, three trials (
Ind 2002;Rabe 2006;Tattersfield 2001) reportedmeandaily doses
of 1.9 to 3.9 puffs a day (8.5 to 17.5 µg) which is of the order of
recommended maintenance formoterol doses (12 µg twice daily,
BNF).
All participants in Ind 2002 were on maintenance formoterol as
a study medication in addition to constant dose of inhaled cor-
ticosteroids and randomised as-needed formoterol or terbutaline.
All participants in Rabe 2006 were originally on inhaled corti-
costeroids and were then moved to budesonide/formoterol at a
dose on which they were symptomatic in addition to randomised
formoterol or terbutaline. Participants in SD-037-0714 were on
inhaled corticosteroids at different but constant doses and were
not permitted other long-acting beta2-agonists. Participants in
Tattersfield 2001 stayed on the same dose of inhaled corticos-
teroids or othermaintenance medications and participants in Villa
2002 were on inhaled corticosteroids, disodium cromoglycate or
nedocromil at a constant dose. Any ordinary asthma medication
apart from relievers was permitted in RELIEF 2003, and sub-
group data by background medication were reported for serious
adverse events, discontinuations due to serious adverse events and
exacerbations. Patients in RELIEF 2003 were able to have their
prescriptions for maintenance medication changed in response to
changing asthma. Participants in SD-037-0716 were not onmain-
tenance medication. It was not stated whether patients were on
any sort of maintenance medication in the abstract located for Jain
2004.
RELIEF 2003 was the only trial to employ pressurised metered
dose inhalers; formoterol was delivered via dry powder inhaler in
all countries whereas salbutamol was delivered via a dry powder
inhaler in six countries and by pressurised metered dose inhaler in
18 countries. The other six trials employed dry powder inhalers
for both formoterol and short-acting beta2-agonist.
Participants were instructed to take their relief inhalers as needed
and to tell the investigators if they took more than 10 puffs in
a day (Rabe 2006) or more than 12 puffs (Tattersfield 2001) or
more than 12 puffs in adults and eight puffs in children (RELIEF
2003).
Usage of relief inhalerswas an inclusion criteria in six of the studies,
this was not stated by Jain 2004 and not a criteria for RELIEF
2003. To be eligible for randomisation, participants in Ind 2002
had to have taken between two and five puffs of terbutaline per
day during run-in, those in Tattersfield 2001 had to have taken
between three and eight puffs a day on at least seven days in the
run-in period. Patients in the other trials took fewer inhalations;
those in Rabe 2006 had to have used relief medication on five
out of seven days; participants in SD-037-0714 participants used
fewer than four inhalations per day on at least three occasions
per week; SD-037-0716 used their inhalers on between two and
six occasions during run-in and participants in Villa 2002 used
an average of at least one puff per day during the run-in period.
Asthma severity in the studies is summarised inTable 2with details
of the duration and number of centres for each study.
Patients were withdrawn from the studies if their daily use of relief
medication exceeded certain thresholds. These were eight puffs
per day (N = 2), 10 puffs (N = 1) and 12 puffs (N = 2).
Outcomes
The primary outcomes for the studies did not necessarily match
ours because the aim of individual trials was to show that for-
moterol is as effective as short-acting beta2-agonists and there was
some variation across studies. Time until first asthma exacerba-
tion as the primary outcome was used in four studies (Rabe 2006;
RELIEF 2003; Tattersfield 2001; Villa 2002). Peak expiratory
flow was employed as the primary outcome by SD-037-0714 and
SD-037-0716 whilst Ind 2002 used serumpotassium levels, ECG,
vital signs, lung function and adverse events.
However, data for our primary outcomeswerewell-reported and so
we were able to use these in our review. Patients with exacerbations
requiring hospitalisation were reported in seven studies; patients
with exacerbations requiring oral corticosteroids in six studies and
fatal serious adverse events in four studies and non-fatal serious
adverse events in seven studies. Our secondary outcomes were
also well-reported. We did not find separate details of results from
children in those studies that included both adults and children.
Excluded studies
Full details can be found in the Characteristics of excluded studies
tables.
Risk of bias in included studies
A summary of the risk of bias in the included studies is shown in
Figure 1
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
All eight trials were described as randomised. Three trials (Rabe
2006; RELIEF 2003; Tattersfield 2001) gave detailed descriptions
of satisfactory sequence generation and allocation concealment.
Four trials did not provide such clear descriptions (Ind 2002;
SD-037-0714; SD-037-0716; Villa 2002); however the sponsor
provided details of adequate randomisation. Jain 2004 was de-
scribed as randomised with no further details, and so sequence
generation and allocation concealment remains at unclear risk of
bias.
Blinding
Six trials overall were described as double-blind; neither patient
nor investigator knew to which as-needed medication an individ-
ual was randomised. Blinding was preserved by delivering medi-
cations via identical inhalers. Three studies provided detailed de-
scriptions of how the patients were blinded (Ind 2002; Rabe 2006;
Tattersfield 2001) and the sponsors provided suitable descrip-
tions of the blinding for the remaining three trials (SD-037-0714;
SD-037-0716; Villa 2002). In three trials (Tattersfield 2001;
SD-037-0714; SD-037-0716) the blinding was lifted in the case
of a serious adverse event and so was judged as unclear risk of bias
for the subjective outcomes.
RELIEF 2003 was an open-label study that did not attempt to
blind the participants or investigators. This is unlikely to have
affected objective outcome measures (hospitalisations, all-cause
serious adverse events, deaths) which was judged to be at low
risk of bias. However, the open-label design may have affected
subjective outcomes and was judged to be at unclear risk of bias for
this domain. Bias may result from having unblinded investigators,
who may consciously or subconsciously make different decisions
on whether to give a patients a course of oral corticosteroids or
in judging whether or not a serious adverse event was related to
asthma. In addition, knowledge of the study drug may affect a
patient’s decision to withdraw from the study.
Incomplete outcome data
Six trials were judged to be at low risk of bias from incomplete
outcome reporting (Rabe 2006; RELIEF 2003; SD-037-0714;
SD-037-0716; Tattersfield 2001; Villa 2002) and all trials were
analysed on an intention-to-treat basis. Five trials reported reasons
for withdrawals and were balanced between treatment arms (Rabe
2006; RELIEF 2003; SD-037-0714; SD-037-0716; Tattersfield
2001). Although Villa 2002 did not provide reasons for with-
drawal, it was judged to be low risk of bias because the numbers of
withdrawals were similar to those in other trials in this review and
balanced between treatment arms (Table 3). Ind 2002 was judged
to be at unclear risk of bias due to incomplete outcome data, be-
cause although numbers of withdrawals were reported it was not
clear how many withdrawals corresponded to each treatment arm.
Jain 2004 was judged to be at unclear risk of incomplete outcome
data bias because the number of withdrawals, if any, was not dis-
closed in the abstract.
Additionally, Ind 2002 reported only run-in data for FEV1 or PEF
and stated that this remained unchanged throughout the treat-
ment period. We felt it was unlikely that the mean and standard
deviation stayed constant throughout this whole period, but since
there were no data to enter into the meta-analysis this judgement
did not effect the outcome of our meta-analysis.
Selective reporting
Six trials were judged to be of low risk of selective outcome re-
porting bias (Ind 2002; Rabe 2006; RELIEF 2003; SD-037-0714;
SD-037-0716; Tattersfield 2001). Villa 2002 was judged to be at
unclear risk of selective outcome reporting bias because some key
data (PEF, number of inhalations, night-time awakenings, days
restricted activity, FEV1, quality of life, adverse events) relevant
to our study or stipulated as outcomes in the study report, were
missing from the study report. Jain 2004 was also at unknown
risk of bias in this domain but since there was a single abstract
published and we cannot be sure of the missing results.
Other potential sources of bias
Villa 2002 was judged to be at high risk of publication bias be-
cause the study has only been published as a study report and an
abstract and therefore lacks information on study characteristics
and outcome data. Jain 2004 was also at high risk of publication
bias since it was published as a single abstract. Although it is debat-
able whether trials that have only been reported as abstract should
be included in Cochrane systematic reviews, these two trials were
small and did not have a meaningful effect on the results of the
meta-analysis and so they remain in the review as a record.
Exacerbations were assessed subjectively by the investigator in
some of the trials (Ind 2002; Rabe 2006; RELIEF 2003; SD-037-
0714; SD-037-0716; Tattersfield 2001), although a drop in PEF
of > 30% was also considered an exacerbation by Ind 2002 and
Tattersfield 2001. None of the trials reported explicit definitions
of asthma-related serious adverse events, and they used patient re-
ported asthma aggravated events where described.
All the trials apart from Jain 2004 were sponsored by AstraZeneca.
Effects of interventions
See: Summary of findings for the main comparison Formoterol
versus short-acting beta2-agonist as relief medication for asthma
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There was only one trial conducted in children (Villa 2002, N =
552), and trials that were conducted in children and adults did not
provide separate paediatric data. Therefore there was insufficient
paediatric data presented tomerit a full subgroup analysis. We also
found that subgroup analysis by asthma severity was not feasible
due to the overlap in asthma severities in the various trials.
In the majority of the meta-analyses, heterogeneity was not en-
countered. The I2 statistic is only mentioned in the discussion
below when it is not equal to zero. All meta-analyses were com-
pared with both the Peto odds ratio and/or the Mantel-Haenszel
random-effects model. There was no difference in these sensitivity
analyses except for withdrawals.
Primary outcomes
Patients with an exacerbation requiring hospitalisation
Overall seven trials provided data on hospital admissions for
22,236 participants (Ind 2002; Jain 2004; Rabe 2006; RELIEF
2003; SD-037-0714; SD-037-0716; Villa 2002). There were
fewer hospitalisations in participants on formoterol than in those
on short-acting beta2-agonist (OR 0.84; 95% CI 0.67 to 1.04),
however this was not statistically significant (Figure 2). Sixteen
patients on short-acting beta2-agonists out of 1000 had hospital-
isations over 30 weeks, compared to 13 (95% CI 11 to 17) out
of 1000 in patients on formoterol but this confidence interval in-
cludes the possibility that there is no difference between the treat-
ments.
Figure 2. Forest plot of comparison: 1 Formoterol versus short-acting beta2-agonist, outcome: 1.1 Patients
with an exacerbation requiring hospitalisation.
Rabe 2006 reported serious adverse events reported as asthma and
this was used as a proxy measure for hospitalisations. Two trials
(Ind 2002; Jain 2004) reported events rather than the number
of participants experiencing an event, which could lead to tighter
confidence intervals than representative of the true treatment ef-
fect if any participants had experienced more than one hospital
admission.
Patients with an exacerbation requiring a course of oral
corticosteroids
Six trials contributed data on exacerbations requiring a course of
oral corticosteroids for 21,591 participants (Ind 2002; Jain 2004;
Rabe 2006;RELIEF 2003; SD-037-0716;Villa 2002). Therewere
fewer exacerbations requiring a course of oral corticosteroids in
patients of formoterol than those on short-acting beta2-agonists
(OR 0.84; 95% CI 0.77 to 0.91) which was a statistically signif-
icant difference (Figure 3; Analysis 1.2). In patients on short-act-
ing beta2-agonists, 117 people out of 1000 had exacerbations re-
quiring oral corticosteroids over 30 weeks, compared to 101 (95%
CI 93 to 108) out of 1000 for patients on formoterol as-needed
(Figure 4).
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Figure 3. Forest plot of comparison: 1 Formoterol versus short-acting beta2-agonist, outcome: 1.2 Patients
with an exacerbation requiring a course of oral corticosteroids.
Figure 4. In patients on short-acting beta2-agonists, 117 people out of 1000 had exacerbations requiring
oral corticosteroids over 30 weeks, compared to 101 (95% CI 93 to 108) out of 1000 for patients on formoterol
as-needed.
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We calculated data for RELIEF 2003 by subtracting hospitalisa-
tions from severe exacerbations, but the reduction in exacerbations
is still significant when data from RELIEF 2003 are excluded.
Jain 2004 reported events rather than the number of participants
experiencing an event, which could again lead to an over-precise
estimate of the treatment effect, however performing a sensitivity
analysis by removing this study did not significantly alter the esti-
mate of treatment effect. Data were provided by the sponsors for
Rabe 2006.
Exacerbations requiring a course of oral corticosteroids in
relation to maintenance medication use
Four studies contributed to a subgroup analysis for exacerbations
requiring a course of oral corticosteroids according tomaintenance
inhaled corticosteroid use (Figure 5; Analysis 2.1) on 3669 pa-
tients. Patients in Ind 2002, Rabe 2006 and Tattersfield 2001 were
on maintenance inhaled corticosteroids as either a randomised
dose of budesonide/formoterol (Rabe 2006) or non-randomised
inhaled corticosteroids at a stable dose (Ind 2002; Tattersfield
2001). Among these patients, there were fewer exacerbations re-
quiring a course of oral corticosteroids in patients on formoterol
than those on short-acting beta2-agonists (Peto OR 0.75; 95%
CI 0.62 to 0.91) which was a statistically significant improve-
ment. There was only one trial that we could ascertain was con-
ducted in patients who were not taking inhaled corticosteroids
(SD-037-0716) and there was no statistically significant difference
in exacerbations requiring oral corticosteroids for this study (Peto
OR 1.47; 95% CI 0.70 to 3.10). Although these treatment effects
were in opposite directions, there was no significant difference in
the test for subgroup differences (Chi² = 2.94, df = 1 (P = 0.09)) so
a relationship between exacerbations requiring oral corticosteroids
and maintenance inhaled corticosteroids was neither proved or
disproved.
Figure 5. Forest plot of comparison: 2 Formoterol versus short-acting beta2-agonist (background ICS use),
outcome: 2.1 Patients with an exacerbation requiring a course of oral corticosteroids.
Fatal serious adverse events (all-cause)
Five trials on 21,629 participants provided mortality data (Figure
6, Analysis 1.3). There was one death per 1000 people on both
formoterol and on short-acting beta2-agonists used for relief of
symptoms (OR 1.08; 95% CI 0.51 to 2.30). These trials are un-
derpowered to detect a difference in mortality rates and an unfea-
sibly large trial would be required to do this.
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Figure 6. Forest plot of comparison: 1 Formoterol versus short-acting beta2-agonist, outcome: 1.3 Fatal
serious adverse events (all-cause).
There were three deaths in Rabe 2006, one on formoterol as-
needed and two on terbutaline as-needed, but none of these were
judged by the study investigator to be related to the study drug
and none were reported as asthma. In RELIEF 2003, there were
13 deaths in patients on formoterol as-needed of which three were
judged to be related to asthma, and 11 deaths in patients on salbu-
tamol as-needed, of which two were deemed related to asthma.
Patients with a serious adverse event (all-cause)
Seven trials provided data on serious adverse events in 22,538 par-
ticipants (Ind 2002; Rabe 2006; RELIEF 2003; SD-037-0714;
SD-037-0716; Tattersfield 2001; Villa 2002). Overall there were
fewer serious adverse events from any cause in patients on for-
moterol than in patients on short-acting beta2-agonists but this
difference did not reach statistical significance (OR 0.94; 95% CI
0.81 to 1.08), see Figure 7 (Analysis 1.4). In patients on short-
acting beta2-agonists, 35 people out of 1000 had serious adverse
events (all-cause) over 30 weeks, compared to 33 (95% CI 29 to
38) out of 1000 in patients on formoterol but the confidence inter-
val includes the possibility that there is no difference between the
treatments. There was a small amount of statistical heterogeneity
(I2 = 9%). Data were entered into the meta-analysis as the number
of patients experiencing one or more serious adverse events in six
cases (Rabe 2006; RELIEF 2003; SD-037-0714; SD-037-0716;
Tattersfield 2001; Villa 2002) and as the total number of events
in Ind 2002, although performing a sensitivity analysis without
this trial did not significantly alter the estimate of the treatment
effect. Three trials reported patients experiencing more than one
exacerbation (Rabe 2006; RELIEF 2003; Villa 2002) and further
details can be found in the Characteristics of included studies.
Figure 7. Forest plot of comparison: 1 Formoterol versus short-acting beta2-agonist, outcome: 1.4 Patients
with a serious adverse event (all-cause).
Serious adverse events (all-cause) in relation to maintenance
medication use
All seven trials provided data and could be analysed by subgroup
according to maintenance inhaled corticosteroids, or lack thereof
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(Figure 8, Analysis 2.2). Five trials were conducted in patients
whowere onmaintenance inhaled corticosteroids (Ind 2002; Rabe
2006; SD-037-0714; Tattersfield 2001; Villa 2002) and separate
data were available for this outcome in RELIEF 2003. There were
fewer all-cause serious adverse events in patients randomised to
formoterol who were also on maintenance inhaled corticosteroids,
although this difference did not reach statistical significance (OR
0.91; 95%CI0.78 to 1.06). Therewas a small amount of statistical
heterogeneity found (I2 = 25%). In patients who were not taking
inhaled corticosteroids (RELIEF 2003; SD-037-0716) there were
fewer serious adverse events in patients on short-acting beta2-ago-
nists although this difference did not reach statistical significance
(OR 1.14; 95% CI 0.77 to 1.69). Although there was a difference
in the direction of the treatment effects for each subgroup, the
test for subgroup differences (Chi² = 1.17, df = 1 (P = 0.28)) did
not show a significant interaction between maintenance inhaled
corticosteroids and all-cause serious adverse events.
Figure 8. Forest plot of comparison: 2 Formoterol versus short-acting beta2-agonist (background ICS use),
outcome: 2.2 Patients with a serious adverse event (all-cause).
We also performed a subgroup analysis on the basis ofmaintenance
long-acting beta2-agonist use or lack thereof (Analysis 3.1). Three
trials contributed data for patients who were taking maintenance
long-acting beta2-agonists (Ind 2002; Rabe 2006; RELIEF 2003).
There were fewer all-cause serious adverse events in patients on
formoterol compared to those on short-acting beta2-agonist, al-
though this did not reach statistical significance (OR 0.84; 95%
CI 0.68 to 1.03). In patients who were not taking long-acting
beta2-agonist as maintenance, there was no significant difference
in serious adverse events in those on formoterol or short-acting
beta2-agonists (OR 1.06; 95% CI 0.86 to 1.30). The test for sub-
group difference did not show a statistically significant difference
in the treatment effects in patients on background long-acting
beta2-agonists compared to those on none (Chi² = 2.44, df = 1 (P
= 0.12)).
Patients with a serious adverse event (asthma-related)
Six trials reported asthma-related serious adverse events in 21,986
participants (Ind 2002; Rabe 2006; RELIEF 2003; SD-037-0714;
SD-037-0716; Tattersfield 2001). These trials showed fewer
asthma-related serious adverse events in patients on formoterol
than in patients on short-acting beta2-agonists, although this dif-
ference did not reach statistical significance (OR 0.91; 95% CI
0.72 to 1.15), see Figure 9. In patients on short-acting beta2-ag-
onists, 14 people out of 1000 had asthma-related serious adverse
events over 30 weeks, compared to 13 (95% CI 10 to 16) out
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of 1000 for patients on formoterol as-needed. Although number
of events was reported, the sponsors provided data on the num-
ber of patients experiencing an event from three trials (Ind 2002;
SD-037-0714; SD-037-0716).
Figure 9. Forest plot of comparison: 1 Formoterol versus short-acting beta2-agonist, outcome: 1.5 Patients
with a serious adverse event (asthma-related).
Secondary outcomes
Peak expiratory flow (PEF)
Patients on formoterol showed a greater improvement in morning
PEF than those on short-acting beta2-agonists (MD 3.88 L/min;
95% CI 1.29 to 6.46), and this was a small but statistically signif-
icant result (Analysis 1.6). There was a small amount of statistical
heterogeneity (I2 = 17%). Again, patients on formoterol showed
a greater improvement in evening PEF than those on short-acting
beta2-agonists (MD 2.05 L/min; 95% CI -0.50 to 4.60), however
this difference was not statistically significant (Analysis 1.7).
Fixed expiratory flow in one second (FEV1)
One study reported a modest change in FEV1 in litres (Rabe
2006). There was an improvement in FEV1 of 30 mL (MD 0.03
L; 95% CI 0.00 to 0.06).
Three studies reported change in % predicted FEV1 (SD-037-
0714; SD-037-0716; Tattersfield 2001). These studies favoured
formoterol (MD 0.61%; 95% CI -0.49 to 1.71), but this differ-
ence was not statistically significant. There was a large amount of
heterogeneity in this result (I2 = 85%).There was clinical hetero-
geneity in the baseline values which might explain the statistical
heterogeneity observed; two studies had mean baseline FEV1 %
predicted close to 100% (SD-037-0714; SD-037-0716), whilst
Tattersfield 2001 had a lower mean FEV1 % predicted at baseline
(74%).
Symptoms (day-time)
Five studies provided information on symptoms (Rabe 2006;
RELIEF 2003; SD-037-0714; SD-037-0716; Tattersfield 2001),
but the unit of analysis varied. Rabe 2006 reported change from
run-in on an asthma symptom score scale from zero to six. Par-
ticipants in Rabe 2006 on formoterol showed an improvement
in symptoms of -0.58 and participants on terbutaline showed an
improvement of -0.57 which did not result in a significant differ-
ence between the two treatments (MD 0.1; 95% CI -0.05 to 0.07)
(Analysis 1.8). SD-037-0714, SD-037-0716 andTattersfield 2001
reported symptom scores on a scale of zero to four, but there was
no significant difference between scores.
Nocturnal awakenings
Two studies reported nocturnal awakenings. Rabe 2006 reported
no significant difference in the adjusted mean change from run-in;
patients on formoterol reported an improvement of -14.0% and
patients on formoterol a -13.5% reduction in awakenings (MD -
0.60; 95% CI -2.25 to 1.05). Tattersfield 2001 also reported no
significant difference in nocturnal awakenings (MD 0.00, 95%
CI -0.10 to 0.10).
Quality of life
Tattersfield 2001 reported data for quality of life, using the Asthma
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Quality of Life Questionnaire (AQLQ)measured on a scale of zero
to seven. There was an improvement of 0.41 units in patients on
formoterol as-needed and 0.17 units in patients on terbutaline as-
needed which was a statistically significant difference (MD 0.24;
95% CI 0.09 to 0.39), but the minimally important difference to
the individual is 0.5 units.
Withdrawals (any reason)
Seven trials provided data for the number of withdrawals (Ind
2002; Rabe 2006; RELIEF 2003; SD-037-0714; SD-037-0716;
Tattersfield 2001; Villa 2002). The numbers of withdrawals varied
between 4.8% and 13% per treatment arm across all the studies
(Table 3). There were more withdrawals in patients on formoterol
compared to short-acting beta2-agonists (OR fixed-effect 1.12;
95% CI 1.02 to 1.24) and this was statistically significant. How-
ever, there is statistical heterogeneity present which merits further
discussion (I2 = 71%).
This meta-analysis is dominated by RELIEF 2003, a trial in which
the majority of withdrawals were from patients on formoterol, in
contrast to the other studies that have more withdrawals in pa-
tients on short-acting beta2-agonists. The population-wide, open-
label design of RELIEF 2003 in comparison to the double-blind
nature of the other trails may account for part of this difference.
Performing sensitivity analysis by removing trials at high risk of
bias for this outcome, which in this case is RELIEF 2003, gives a
statistically significant result in favour of short-acting beta2-ago-
nists (OR 0.80; 95% CI 0.67 to 0.96).
The RELIEF 2003 trialists report a statistically significant treat-
ment interaction for asthma-related discontinuations by inhaler
type. In the countries where both medications were delivered
by dry powder inhalers, the numbers of discontinuations due to
asthma-related adverse events were balanced across both treat-
ments (28 (1.1%) in patients on formoterol and 24 (1.0%) in
patients on salbutamol, P = 0.61). However in countries where
salbutamol was delivered by pressurised metered dose inhaler there
were more discontinuations due to asthma-related adverse events
in patients on formoterol (61 (1%) compared to 25 (0.4%), P <
0.001). Discontinuation may therefore have been related to the
change from metered dose inhaler to dry powder delivery for pa-
tients who used formoterol as a reliever in RELIEF 2003.
D I S C U S S I O N
There were eight included studies, of which two were reported
only as an abstract. Participants in five of the studies were on a
maintenance inhaled corticosteroid (one with maintenance for-
moterol plus and inhaled corticosteroid and one on a budesonide/
formoterol combined inhaler) and patients in the largest trial were
allowed to take any normal medication. The short-acting beta2-
agonist was terbutaline in six trials and salbutamol in two. Most
of the studies employed dry powder inhalers. All the studies apart
from a large open-label effectiveness study were double-blind. De-
spite these differences we judged that it was possible to look at the
major endpoints laid out in our protocol.
Summary of main results
Asthma exacerbations and serious adverse events showed a direc-
tion of treatment effect favouring formoterol, of which one pri-
mary outcome reached statistical significance (exacerbations re-
quiring a course of oral corticosteroids). In patients on short-act-
ing beta2-agonists, 117 people out of 1000 had exacerbations re-
quiring oral corticosteroids over 30 weeks, compared to 101 (95%
CI 93 to 108) out of 1000 for patients on formoterol as-needed.
There were fewer exacerbations requiring a course of oral corti-
costeroids in the subgroup of patients taking maintenance inhaled
corticosteroids on formoterol as-needed than those on short-acting
beta2-agonists. Although study participants not on background
inhaled steroids appeared to be at a greater risk of exacerbations
than those on inhaled steroids (Analysis 2.1), the subgroup differ-
ence did not reach statistical significance. We remain uncertain as
to the nature and strength of the relationship between concurrent
inhaled steroid exposure and the risk of exacerbations requiring
oral corticosteroids. There were few deaths in the studies and con-
sequently there were wide confidence intervals around the risk of
death. In the control group one person out of 1000 died over 30
weeks, compared to one (95%CI 1 to 3) out of 1000 for the active
treatment group.
Overall completeness and applicability of
evidence
There were few studies of formoterol versus short-acting beta2-
agonists as-needed conducted solely in children and a lack of sep-
arate paediatric data in other trials. Therefore in order to apply
the results of this systematic review to children, one would have
to assume that children have the same response to these drugs as
adults. A review of maintenance formoterol in patients who were
not takingmaintenance inhaled corticosteroids showed an increase
in adverse events in serious adverse events in children compared
to adults (Cates 2008a). Our results therefore cannot be safely ap-
plied to children.
There were limited data for subgroups according to background
maintenance inhaled corticosteroid or long-acting beta2-agonist
therapy.
There was a broad range of asthma severities included in the trials
and itwas not possible to separate outcomedata by asthma severity,
so we cannot apply evidence in this review to populations with
specific asthma severities.
Participants in three studies (Rabe 2006; Tattersfield 2001; Villa
2002) demonstrated reversibility to terbutaline, whereas partic-
ipants were not tested for reversibility in four trials (Ind 2002;
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RELIEF 2003; SD-037-0714; SD-037-0716) and we are not sure
whether or not reversibility was tested in Jain 2004. This might
limit the applicability of our findings.
Quality of the evidence
Most of the studies we found were good quality trials in terms
of randomisation and blinding, although Jain 2004 was reported
as a single abstract the author did not provide more information.
Removing this trial from the meta-analysis did not markedly af-
fect the results. Although there is a risk of detection bias from
RELIEF 2003 being open-label, particularly with respect to sub-
jective outcomes, excluding it from the meta-analyses did not ac-
tually change the direction or statistical significance of the pooled
treatment effects. Its impact on the estimate of withdrawals was
more substantial, with the direction of the result moving in favour
of short-acting beta2-agonist.
The studies and also our systematic review were underpowered to
detect a difference in mortality. Because of the low incidence of
death in asthma clinical trials, an unfeasibly large trial would be
required to demonstrate a difference in mortality (Rodrigo 2010;
Wijesinghe 2009).
The studies employed different as-needed medications, inhalers
and background medication. In addition themajor trial was open-
label in comparison to the other trials which were double-blind.
The considerable differences between the trialsmaymake the com-
bined results harder to interpret.
Summary of findings table
We downgraded evidence for the subjective outcomes (exacerba-
tions requiring oral corticosteroids, asthma-related serious adverse
events and withdrawals) because we felt that these were subject to
bias due to the large open-label trial. Although this trial might be
more like “real life”, a double-blind trial of the same size might
change the results of the review. Exacerbations leading to hospital-
isations was downgraded because the confidence interval included
the possibility of no difference in treatment effect. Deaths were
downgraded twice for imprecision due to the sparsity of events
and the width of the confidence interval. Withdrawals was down-
graded by an additional point because there was significant het-
erogeneity for this outcome.
Potential biases in the review process
The review process was protected from bias by following a pre-
published protocol. We minimised bias by assessing studies in-
dependently and resolving differences of opinion by discussion.
Data extraction was also performed in duplicate. We consulted
the manufacturer of formoterol and asked if they could identify
other published or unpublished reports of their trials, and provide
unpublished data and clarification of data that we calculated from
available information. We only performed subgroup analyses that
were specified a priori in the protocol.
Agreements and disagreements with other
studies or reviews
Of current concern in asthma management is whether treatment
with regular long-acting beta2-agonists such as formoterol masks
deterioration in asthma due to non-control of underlying inflam-
mation with inhaled corticosteroids (Pavord 2009). The average
dose used of formoterol as-needed (8.5 to 17.5 µg) was of the
order of the recommended maintenance formoterol dosage (12
µg twice daily). Patients on formoterol “as-needed” may there-
fore be subject to increased risks of serious adverse events if they
are not taking regular inhaled corticosteroids. It is not recom-
mended to take formoterol without taking inhaled corticosteroids
(BTS/SIGN 2008; Cates 2008a; Cates 2009b; FDA website).
Patients tend to increase their reliever therapies rather than their
inhaled corticosteroids when their asthma worsens. Therefore,
a more pertinent clinical question than whether formoterol as-
needed is better than short-acting beta2-agonists as-needed, at least
in high-income countries, is whether single inhaler therapy is su-
perior to separate inhalers. The studies described in this review
were designed by the sponsors to demonstrate whether formoterol
as a reliever is as safe and effective as short-acting beta2-agonists,
and this allowed development of single inhaler therapy for the
maintenance and relief of symptoms.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In adults, formoterol was similar to short-acting beta2-agonists
when used as a reliever and showed a reduction in the number
of exacerbations requiring a course of oral corticosteroids. Clin-
icians should weigh the relatively modest benefits of formoterol
as-needed against the benefits of single inhaler therapy and the
potential danger of long-term use of long-acting beta2-agonists in
some patients. We did not find evidence to recommend changes
to guidelines that suggest that long-acting beta2-agonists should
be given only to patients already taking inhaled corticosteroids.
There was insufficient information reported from children in the
included trials to come to any conclusion on the safety or efficacy
of formoterol as relief medication for children with asthma.
Implications for research
Further research is required to clarify the safety and efficacy of
formoterol as a reliever in children.
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Assessing differences in mortality rates in a study comparing for-
moterol to short-acting beta2-agonists is hampered by the require-
ment for very large numbers of patients. A double-blind trial of
the same size as RELIEF 2003 may offer further, more reliable,
information on the differences in efficacy in relation to adverse
events and exacerbations although it is difficult to recommend
that a trial of this nature should be conducted in patients who
are not already receiving maintenance inhaled corticosteroids. It
is also questionable whether there would be sufficient interest in
the results of such a study, in view of the advent of maintenance
and reliever therapy with combined inhaled corticosteroid and
formoterol inhalers.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ind 2002
Methods Study design: randomised, double-blind, parallel-group
Study duration: 12 weeks
Number of study centres and location: 42 centres in 5 countries (the UK, Spain, Israel,
Finland and Hungary)
Participants N randomised (males): formoterol maintenance plus formoterol as-needed 176 (67),
formoterol maintenance plus terbutaline as-needed 181 (76)
Withdrawals: formoterolmaintenance plus formoterol as-needed7 and formoterolmain-
tenance plus terbutaline as-needed 1
Age mean (range): 47
Asthma severity: patients had to have been stable on an adequate constant dose of ICS
for > 4 weeks. Patients were also included if ≤ 10 mg per day of oral prednisolone or
equivalent
Diagnostic criteria: ATS
Baseline ICS use: formoterol maintenance plus formoterol as-needed 1034 µg (200 to
2900), formoterol maintenance plus terbutaline as-needed1030 µg (200 to 3200)
Baseline lung function, FEV1 (% predicted): formoterol maintenance plus formoterol
as-needed 2.23 L (76%), formoterol maintenance plus terbutaline as-needed 2.24 L
(76%)
Inclusion criteria: patients > 18 years with FEV1 > 50% predicted normal. Patients
requiring 2 to 5 inhalations per day of as-needed terbutaline during run-in. Patients
must have completed the run-in according to protocol
Exclusion criteria: patients with significant cardiovascular disease, pregnant or breast-
feeding women or patients with hypersensitivity to lactose or beta2-agonists. Beta2-ago-
nist, anticholinergics, leukotriene receptor agonists, cromones or immunotherapy were
not permitted. Patients who used > 8 inhalations during a single day during run-in
Interventions Run-in: 2 weeks on formoterol 9 µg twice a day and terbutaline Turbuhaler 0.5 mg as-
needed
Intervention: formoterol 9 µg twice a day plus formoterol Turbuhaler 4.5 µg as-needed
Control: formoterol 9 µg twice a day plus terbutaline Turbuhaler 0.5 mg as-needed
Instructions provided for as-needed therapy: “use as-needed medication for either relief
of asthma symptoms or prevention of bronchoconstriction (e.g. before exercise) and to
appraise the effect of each inhalation before proceeding with as second”
Average puffs per day used, mean (range): formoterol as-needed 2.16 (0.0 to 6.3), terbu-
taline as-needed 2.34 (0.1 to 7.5)
Co-medication: all on inhaled or oral corticosteroids at a constant dose
Outcomes Primary outcomes: serum potassium levels, ECG, vital signs, lung function, adverse
events
Secondary outcomes: number of inhalations of as-needed medication, severe asthma
exacerbations, lung function, asthma symptoms
Time points: attended clinic on 5 occasions with telephone calls to check on usage of
reliever medication and adverse events between visits
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Ind 2002 (Continued)
Definition of severe asthma exacerbation: either a requirement for oral glucocorticos-
teroids, either as judged by the investigator or following a drop in PEF on 2 consecutive
days to < 70% of mean baseline value. Treated with 30 mg/day oral prednisolone for 10
days reducing dose by 5 mg/day over the next 5 days. Patients withdrawn after a second
exacerbation
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “randomised”
Allocation concealment? Yes From correspondence: “Patients received
an enrolment code in consecutive order per
centre at visit 1. Eligible patients... were al-
located a randomised patient No. in con-
secutive order, per centre, at visit 2.”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes “Double blind”. Both study drugs admin-
istered by identical inhalers
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Yes “Double blind”
Incomplete outcome data addressed? Unclear The numbers of withdrawals in each treat-
ment arm were not described adequately in
the text
Free of selective reporting? Yes Outcomes reported, although numerical
data not given for PEF and FEV1 apart
froma graph that nodata could be obtained
from
Free of other bias? Yes None noted
Jain 2004
Methods Study duration: 6 months
Participants N completed (males): formoterol 29, salbutamol 31
Interventions Intervention: formoterol 4.5 µg as-needed
Control: salbutamol 100 µg as-needed
Instructions provided for as-needed therapy: formoterol 1 puff as-needed, salbutamol 2
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Jain 2004 (Continued)
puffs as-needed
Average puffs per day used, mean (range):
Outcomes Time points: 30, 90 and 180 days
Notes Completed diary card for 2 weeks prior to 3 data collection visits
This study was reported as an abstract and we were not provided with further details on
request and so the details reported here are limited
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomised”
Comment: not stated, possibly done
Allocation concealment? Unclear Comment: not stated, possibly done
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Unclear Comment: not stated, possibly done
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Unclear Comment: not stated, possibly done
Incomplete outcome data addressed? Unclear Withdrawals not stated
Free of selective reporting? Unclear “data were analysed for safety and efficacy variables”
Comment: since we do not know what outcomes the trial-
ists were planning to measure, we cannot assess this
It was not clear whether hospitalisations or courses of oral
corticosteroids were per event or per individual
Free of other bias? No Publication bias. There was only a single abstract published
on this trial
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Rabe 2006
Methods Study design: randomised, double-blind, parallel-group, active-controlled, phase IIIB
Study duration: 2-week run-in plus 12-month study
Number of study centres and location: 289 centres from 20 countries (Belgium, Bul-
garia, China, Czech Republic, Germany, Greece, Hungary, Indonesia, Italy, Malaysia,
the Netherlands, Norway, the Philippines, Poland, Romania, Russia, Slovakia, South
Africa, South Korea and Vietnam)
Date of study: 10 April 2003 to 21 December 2004
Participants N randomised (males): budesonide/formoterol for maintenance plus formoterol as-
needed 1140 (458), budesonide/formoterol for maintenance plus terbutaline as-needed
1141 (450)
Withdrawals: budesonide/formoterol single inhaler plus formoterol as-needed 132,
budesonide/formoterol single inhaler plus terbutaline as-needed 122
Age, mean (range): 42 (12 to 81)
Asthma severity: moderate to severe asthma and documented symptoms despite use of
ICS
Diagnostic criteria: ATS
Baseline ICS use: all on ICS. Budesonide/formoterol single inhaler plus formoterol 758
µg (320 to 1600), budesonide/formoterol single inhaler plus terbutaline 751 µg (250
to 1600)
Baseline lung function, FEV1 [range] (% predicted): budesonide/formoterol single in-
haler plus formoterol 2.20 L [0.74 to 4.58] (72%), budesonide/formoterol single inhaler
plus terbutaline 2.16 L [0.68 to 4.58] (72%)
Inclusion criteria: outpatients > 12 years, clinical diagnosis of asthma for ≥ 6 months
with > 1 severe asthma exacerbation in the 12 months before entry. All patients used
ICS for ≥ 3 months and at a constant dose for 4 weeks prior to study. FEV1 ≥ 50%
predicted with ≥ 12% reversibility after inhalation of 1 mg terbutaline. Used reliever
medication on 5 or more of the last 7 days of run-in
Exclusion criteria: any respiratory infection affecting the patients asthma or use of OCS
within 1 month of study entry
Interventions Run-in: 2 weeks. Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 µg 1 inhala-
tion twice a day as maintenance and terbutaline turbuhaler 0.5 mg per inhalation as-
needed
Intervention: budesonide/formoterol Turbuhaler 160/4.5 µg 1 inhalation twice a day as
maintenance and formoterol turbuhaler 4.5 µg as-needed
Control: budesonide/formoterol Turbuhaler 160/4.5 µg 1 inhalation twice a day as
maintenance and terbutaline turbuhaler 0.4 mg per inhalation as-needed
Instructions provided for as-needed therapy: “patients were instructed to use their reliever
medication for asthma symptoms, but not prophylaxis. During treatment, patients were
not allowed to use more than ten inhalations of reliever medication a day.”
Average puffs per day used, mean (range): formoterol as-needed 1.90 (0.00 to 9.14),
terbutaline as needed 1.91 (0.30 to 9.73)
Co-medication: participants stopped taking ICS at baseline and started taking budes-
onide/formoterol
Definition of severe asthma exacerbation: deterioration in asthma resulting in emergency
treatment or hospitalisation or the need for oral steroids for 3 days or more (as judged
by the investigator)
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Rabe 2006 (Continued)
Outcomes Primary outcome: time to first severe asthma exacerbation (hospitalisation of ER/ED
visit, course of OCS lasting at least 3 days as judged by the investigator). Days with OCS
recorded
Secondary outcomes: number of severe and mild asthma exacerbations, number of hos-
pitalisations/ED visits, intake of maintenance medication, FEV1, FVC, morning and
evening PEF, asthma symptom score, inhalations of as-needed medication, night awak-
enings due to asthma symptoms, as-needed free days, time to first mild exacerbation,
patient recorded outcomes and asthma control questionnaire, health economics resource
utilisation and sick days. Percentage of asthma control days (24 hours with no symptoms,
no intake of as-needed medication and no night-time awakening due to asthma). Safety
variables were nature, incidence and severity of adverse events
Time points: beginning and end of run-in and after 1, 4, 8 and 12 months of study
treatment
Notes There were 71 serious adverse events in 55 patients on formoterol compared to 83 events
in 65 patients on terbutaline
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisation schedule computer gener-
ated at AstraZeneca Research and Devel-
opment, Charnwood UK, by a person in-
dependent of the study team.”
Allocation concealment? Yes “Within each study centre, eligible patients
were sequentially assigned a randomisation
code by the investigator from the computer
generated list.”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes “as all needed study medication was given
via identical turbuhalers, all matched in ap-
pearance.”
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Yes As above
Incomplete outcome data addressed? Yes Full analysis set included all randomised
patients who provided data after randomi-
sation. Reasons given for withdrawal simi-
lar across arms
Free of selective reporting? Yes All the outcomes that we were interested in
were reported
Free of other bias? Yes None noted
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RELIEF 2003
Methods Study design: Multi-national, multi-centre, randomised, open, parallel-group
Study duration: 6 months
Number of study centres and location: 1139 in 24 countries
Date of study: 17 April 2000 to 24 June 2001
Participants N randomised (males): formoterol 8924 (3924), salbutamol 8938 (3798)
Withdrawals: formoterol 664, salbutamol 525
Age, mean (range): 39 (4 to 91)
Asthma severity: any allowed, defined by use of maintenance treatment at entry as
intermittent (no maintenance treatment), mild (ICS < 500 µg per day or regular LABA,
cromone, theophylline or leukotriene modifier), moderate (ICS alone≥ 500 µg per day
or ICS 500 to 800 µg per day in combination with LABA, theophylline or leukotriene
modifier) and severe (ICS > 800 µg per day in combination with LABA, theophylline
or leukotriene modifier, or oral corticosteroids)
Intermittent: 16%, mild: 35%, moderate: 35%, severe: 15%
Diagnostic criteria: judged by asthma medication levels, GINA
Baseline ICS use: 76% using ICS. Mean usage at baseline 753 µg (formoterol group),
763 µg (salbutamol group)
Baseline LABA use: 31%
Baseline lung function, FEV1 (% predicted): not reported
Inclusion criteria: ≥ 6 years, previous use of or candidates for beta2-agonist reliever
therapy
Exclusion criteria: women who were pregnant, breast-feeding or not using appropriate
contraception. Patients with concomitant cardiovascular diseases were included at physi-
cians’ discretion
Interventions Run-in: none
Intervention: formoterol 4.5 µg, Turbuhaler DPI
Control: salbutamol 200 µg delivered by Turbuhaler dry powder inhaler in 6 countries
and by pressurised metered dose inhaler in 18 countries
Instructions provided for as-needed therapy: patients instructed to contact investigator
if they used more that 12 puffs reliever medication in adults and 8 in children in 1 day,
with lower limits for those on LABA
Average puffs per day used, mean (range): not reported
Co-medication: any ordinary asthma maintenance medication, except other reliever
medication was allowed and investigators could change the maintenance medication
according to clinical judgement
Definitionof asthma exacerbation: any of: 1) increase inmaintenance asthmamedication,
2) course of ICS ≥ 5 days, 3) emergency treatment with nebulised beta2-agonist or
corticosteroid injection, 4) hospitalisation
Definition of severe asthma exacerbation: any of: 1) course of ICS≥ 5 days, 2) emergency
treatment with nebulised beta2-agonist or corticosteroid injection, 3) hospitalisation
Outcomes Efficacy outcomes collected: primary efficacy variable was time to first asthma exacer-
bation. Secondary variables: change in concomitant maintenance asthma medication,
number of inhalations of study drug, number of days with asthma symptoms, health
care resource utilisation, days restricted activity
Safety outcomes collected: primary safety variables were asthma-related and non-asthma-
related serious adverse events and adverse events resulting in discontinuations
Time points: 1, 3 and 6 months
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RELIEF 2003 (Continued)
Notes There were 305 serious adverse events in 278 patients on formoterol compared to 327
events in 299 patients on salbutamol
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “computer generated code”
Allocation concealment? Yes “At entry, patients were randomised in
chronological order at each site, according
to a computer generated code and treat-
ment communicated via code envelope”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes “Open label”
Comment: the study was open-label, but
knowing the assignment of medication is
unlikely to make a difference when judg-
ing when a participant experienced death,
hospitalisation or all-cause serious adverse
event
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Unclear Comment: because the study was open-la-
bel, this may introduce bias when investi-
gators were subjectively judging whether a
serious adverse event was related to asthma
or required a course or oral corticosteroids.
Knowledge of the treatment drug might
influence a patient’s decision to withdraw
from the study
Incomplete outcome data addressed? Yes All analyses were performed on intention-
to-treat population and there were few
withdrawals
Free of selective reporting? Yes The number of outcomes measured was
kept to a minimum as RELIEF was a large
study and they were all reported
Free of other bias? Yes None noted
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SD-037-0714
Methods Study design: double-blind, parallel-group, non-inferiority, therapeutic confirmatory
Study duration: 12 months
Number of study centres and location: 48 centres in Czech Republic, Portugal, Slovak
Republic and South Africa
Date of study: 22 December 2000 to 9 July 2002
Participants N randomised (males): formoterol 228 (113), terbutaline 227 (119)
Withdrawals: formoterol 11, terbutaline 20
Age, mean (range): 25 (6 to 75)
Asthma severity: mild
Diagnostic criteria: GINA
Baseline ICS use, mean (range): on a regular stable dose of ICS formoterol group 376
µg (200 to 900) daily, terbutaline 388 µg (200 to 800) daily
Baseline lung function, FEV1 mean [range] (% predicted): formoterol 2.91 [1.12 to 5.
38] (101%), terbutaline 2.92 [0.96 to 5.77] (100%)
Inclusion criteria: Visit 1: ≥ 6 years old with a diagnosis of asthma (ATS). Baseline
FEV1 ≥ 80% predicted normal. Stable inhaled steroid dose of ≥ 200 but ≤ 500 µg/
day, nedocromyl or cromoglycate treatment for at least 4 weeks prior to enrolment. Visit
2: use of as-needed medication drug between ≥ 3 inhalation occasions/week and ≤ 4
inhalations/day during the run-in period
Exclusion criteria: Visit 1. Use of LABA 3 months prior. Use of a beta-blocker including
eye drops. Respiratory infection affecting the asthma within 4 weeks prior to enrolment,
as judged by the investigator. Smoking history ≥10 pack-years. Women who were
pregnant, breastfeeding or not using an acceptable method of contraception. Visit 2.
< 16 morning PEF values in the diary, any significant respiratory infection, change in
prescribed asthma medication during run-in
Interventions Run-in: 3 weeks terbutaline turbuhaler 0.5 mg single-blind
Intervention: formoterol turbuhaler 4.5 µg
Control: terbutaline sulfate turbuhaler 0.5 mg
Co-medication: ICS, not LABA
Definition of severe asthma exacerbation: the need for oral corticosteroid course or
hospitalisation due to asthma
Outcomes Efficacy outcomes collected: primary variable: average morning PEF over the entire 12-
month period. Secondary variables: FEV1 pre- and post-bronchodilator, evening PEF,
day- and night-time use of study medication, day- and night-time asthma symptoms,
time to first asthma exacerbation, provocative cumulative dose of metacholine giving a
20% fall in FEV1 (PD20).
Safety outcomes collected: adverse events, clinical chemistry, haematology and urinalysis,
ECG, systolic and diastolic blood pressure
Time points: start and end of run-in, at 1, 2, 4, 6, 8, 10 and 12 months plus telephone
call between visits
Notes Full text: Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used
as needed in patients with intermittent or mild persistent asthma. Respiratory medicine
2005;99(4):461-70
Risk of bias
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SD-037-0714 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes “randomised”
Subjects stratified according to age (6 to
11, 12 to 17, ≥18 years) and a different
randomisation list was used for each group
Allocation concealment? Yes From correspondence: patients “who ful-
filled all the inclusion and none of the ex-
clusion criteria were given a randomisation
number at visit 2.” The “randomisation
number was allocated in sequential order.
If a subject discontinued participation in
the study, the number was not re-used.”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes “double blind”
From correspondence: “The study was
double blind and all inhalers were identical
in appearance. The treatment was not to be
prematurely broken unless in an emergency
situation when the appropriate manage-
ment of the subject necessitated knowledge
of the treatment allocation. Prior to break-
ing treatment codes, all decisions taken on
data validation for each individual subject
had to be documented.”
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Unclear From correspondence: the drug safety de-
partment at AstraZeneca could break the
treatment codes if serious adverse events
were suspected to be causally related to the
study medications, if expedited reporting
to authoritieswas required or in exceptional
circumstances for other safety reasons
Incomplete outcome data addressed? Yes The results were analysed on an intention-
to- treat basis. The withdrawals were bal-
anced between arms and in line with other
studies and reasons were provided
Free of selective reporting? Yes None noted
Free of other bias? Yes None noted
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SD-037-0716
Methods Study design: randomised, double-blind, multi-centre, parallel-group
Study duration: 12 months
Number of study centres and location: 54 centres in 8 countries (Estonia, Germany,
Latvia, Lithuania, Poland, Russia, the United Kingdom and Ukraine)
Date of study: February 2001 to June 2002
Participants N randomised (males): formoterol 333 (194), terbutaline 342 (208)
Withdrawals: formoterol 23, terbutaline 28
Age, mean (range): formoterol 23 (6 to 73), terbutaline 24 (6 to 87)
Asthma severity: intermittent
Diagnostic criteria: ATS
Baseline ICS use: not on ICS or LABA
Baseline lung function, FEV1 mean [range] (% predicted): formoterol 3.11 L [0.98 to
5.56] (98%), terbutaline 3.15 L [1.14 to 6.80] (97%)
Inclusion criteria: Visit 1.≥ 6 years old with a diagnosis of asthma according to the ATS.
Baseline FEV1 ≥ 80% predicted normal. Informed consent. Visit 2. Use of SABA on
between 2 and 6 occasions during the last 2 weeks of the run-in
Exclusion criteria: Visit 1. Use of ICS, other anti-inflammatory treatment or LABA 3
months prior. Use of a beta-blocker including eye drops. Respiratory infection affecting
the asthma within 4 weeks prior to enrolment, as judged by the investigator. Smoking
history ≥ 10 pack-years. Use of unallowed medication. Women who were pregnant,
breastfeeding or not using an acceptable method of contraception. Visit 2. < 16 morning
PEF values in the diary, any significant respiratory infection, change in prescribed asthma
medication during run-in
Interventions Run-in: 3 weeks on Bricanyl terbutaline Turbuhaler 0.5 mg as-needed. Single-blind
Intervention: Oxis formoterol Turbuhaler 4.5 µg as-needed
Control: Bricanyl terbutaline Turbuhaler 0.5 mg
Co-medication: not ICS or LABA
Definition of severe asthma exacerbation: the need for oral corticosteroid course or
hospitalisation due to asthma
Outcomes Efficacy outcomes collected: primary variable: average morning PEF over the entire 12-
month period. Secondary variables: FEV1 pre- and post-bronchodilator. Evening PEF,
average daily number of inhalations of as-needed, day- and night-time asthma symptoms,
time to first asthma exacerbation, provocative cumulative dose of metacholine giving a
20% fall in FEV1 (PD20).
Safety outcomes collected: adverse events, clinical chemistry, haematology and urinalysis,
ECG, systolic and diastolic blood pressure
Time points: 1 screening visit, 1 at the end of run-in and after 1, 2, 4, 6, 8, 10 and 12
months treatment. Subjects contacted by phone between visits to check adverse events
and compliance
Notes Full text: Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used
as needed in patients with intermittent or mild persistent asthma. Respiratory medicine
2005;99(4):461-70
Risk of bias
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SD-037-0716 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes “randomised”
Subjects stratified according to age (6 to
11, 12 to 17, ≥18 years) and a different
randomisation list was used fro each group
Allocation concealment? Yes From correspondence: “At visit one all sub-
jects received an enrolment code. The sub-
jects who fulfilled all inclusion and none
of the exclusion criteria were given a sub-
ject number at visit two. Both the enrol-
ment and subject numbers were allocated
in consecutive order. If a subject discontin-
ued participation in the study, this number
was not to be re-used.”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes From correspondence: “The study was
double blind. All inhalers were identical in
appearance”
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Unclear The drug safety department at AstraZeneca
could break the treatment codes if an se-
rious adverse events were suspected to be
causally related to the study medications, if
expedited reporting to authorities was re-
quired or in exceptional circumstances for
other safety reasons
Incomplete outcome data addressed? Yes The results were analysed on an intention-
to-treat basis
Free of selective reporting? Yes None noted
Free of other bias? Yes None noted
Tattersfield 2001
Methods Study design: double-blind, randomised, parallel-group
Study duration: 12 weeks
Number of study centres and location: 35 centres in 4 countries (Greece, theNetherlands,
Norway and Sweden)
Participants N randomised: formoterol 182, terbutaline 180
Withdrawals: 21 formoterol, 32 terbutaline
Age, mean (range): 47 (18 to 75)
Asthma severity: FEV1 > 50% predicted (mild-moderate according to GOLD definition
by FEV1)
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Tattersfield 2001 (Continued)
Baseline ICS use: formoterol 890 µg (200 to 2800), terbutaline 860 (100 to 2400)
Baseline lung function, FEV1 mean [range] (% predicted): formoterol 2.36 L [1.13 to
4.30] (74%), terbutaline 2.27 L [1.00 to 4.65] (74%)
Inclusion criteria: ≥ 18 years, asthma for 6 months or more and been treated with ICS
for > 4 weeks (mean dose 870 µg daily). FEV1 > 50% predicted, and increase in FEV1
of ≥ 12% after inhalation of 1.5 mg terbutaline dry-powder inhaler and used the relief
terbutaline turbuhaler on average 3 to 8 times per day on at least 7 days in the run-in
period
Exclusion criteria: patients who needed more than 12 inhalations per day of relief med-
ication during the run-in period. Patients with a serum potassium value outside the
reference range
Interventions Run-in: 2 weeks on terbutaline Turbuhaler
Intervention: formoterol 4.5 µg (metered dose 6 µg)
Control: terbutaline Turbuhaler 0.5 mg
Instructions provided for as-needed therapy: patients told to take medication only when
needed. Patients taking more than 12 inhalations per day were withdrawn
Average puffs per day used, mean: formoterol as-needed 3.92, terbutaline as-needed 5.
52
Co-medication: Patients were all on ICS. Patients were not allowed to take any oral or
inhaled beta2-agonists during the study period apart from the study medication. Other
asthma medications (xanthines, sodium cromoglycate, nedocromil, antihistamines and
diuretics) were allowed provided that they were kept at a constant dosage throughout
the study
Definition of severe asthma exacerbation: the need for oral corticosteroid course, as
judged by investigator, or decreased PEF of more than 30% from baseline on 2 consecu-
tive days. All severe exacerbations were treated with a 7-day course of oral prednisolone
Outcomes Primary: time to first severe exacerbation
Secondary outcome measures included: morning/evening PEF, FEV1, symptoms, num-
ber of relief medication and safety data, including serum potassium concentration and
changes in electrocardiogram
Time points: start of run-in, start of treatment and after 4, 8 and 12 weeks of treatment.
Contacted by telephone between the last 4 visits to check for adverse events and study
drug consumption
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Patients were randomly assigned to
treatment groups in computer-generated
blocks. The randomisation sequence was
generated by AstraZeneca research andDe-
velopment, Lund.”
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Tattersfield 2001 (Continued)
Allocation concealment? Yes “Investigators assigned a number to each
patient in order. The study drugs were sent
to each centre’s pharmacywith a number al-
located by randomisation before shipping.
”
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes “Investigators were unaware of study drug
assignment throughout the study unless a
SAE occurred.”
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Unclear “double blind”
Incomplete outcome data addressed? Yes Analysed data on an intention-to-treat ba-
sis. Reasons for withdrawal provided, more
withdrawals due to adverse events in the
terbutaline group
Free of selective reporting? Yes None noted
Free of other bias? Unclear None noted
Villa 2002
Methods Study design: randomised, double-blind, parallel-group, reference controlled study, phase
IIIb
Study duration: 6 months
Number of study centres and location: 77 centres in 9 countries
Date of study: 27 Jan 2000 to 26 March 2001
Participants N randomised (males): formoterol 277 (178), terbutaline 275 (180)
Withdrawals: 17 formoterol, 18 terbutaline
Age, mean (range): 11 (5 to 19). Stratified in to 2 age groups 6 to 11 and 12 to 17 years
Asthma severity: mild or moderate persistent. Stable on dose of anti-inflammatory and
more than one dose of as-needed medication
Diagnostic criteria:
Baseline ICS use, mean (range): patients on ICS at baseline, formoterol group 395 µg
(50 to 1400) daily, terbutaline group 406 µg (100 to 1000) daily
Baseline lung function, FEV1 [range] (% predicted): formoterol 1.94 L [0.75 to 4.12]
(83%), terbutaline 1.86 L [0.77 to 3.92] (80%)
Inclusion criteria: patients with bronchial asthma on ICS, disodium cromoglycate or
nedocromil. Visit 1: reversibility in FEV1 (12% from baseline of 9% predicted), on
a stable dose of anti-inflammatory treatment and with a demonstrated need for ≤ 1
inhalation per day of SABA during run-in. Visit 2: average need of > 1 inhalation of
study medication during the last 14 days of run-in and compliant with the electronic
diary
Exclusion criteria: women who were pregnant, breastfeeding or not on acceptable con-
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Villa 2002 (Continued)
traceptives. Subjects who used > 8 inhalations of study medication on any single day,
had more than 3 days with a missing value for number of inhalations or those who had
a respiratory tract infection
Interventions Run-in: 3 weeks
Intervention: formoterol Turbuhaler 4.5 µg as-needed
Control: terbutaline Turbuhaler 0.25 mg as-needed
Co-medication: on ICS, disodium cromoglycate or nedocromil
Outcomes Primary variable: time to first asthma exacerbation (mild or serious)
Secondary:morning and evening PEF, number of inhalations of studymedication, night-
time awakenings due to asthma, days avoiding activity due to asthma symptoms, re-
strictions in activity (all collected days in electronic diary), FEV1 and paediatric Quality
of Life Questionnaire (PAQLQ(S)). Adverse events, ECG variables, pulse and blood
pressure
Time points: 6 months
Notes There were 16 serious adverse events in 15 patients in patients on formoterol compared
to 13 events in 11 patients on terbutaline
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”randomised“
From correspondence: ”Randomisation
lists were computer generated at As-
traZeneca. Lund.“ Stratified according to
age groups
Allocation concealment? Yes From correspondence: ”At visit 1, all sub-
jects received an enrolment code. The sub-
jects who met the inclusion criteria and
none of the exclusion criteria were also
given a randomisation number at visit 2.
If a subject discontinued, that number was
not re-used.“
Blinding?
Objective outcomes; hospitalisation,
deaths, SAEs
Yes ”double-blind“
From correspondence: ”The run-in was
single blind (blind to the subject)
Blinding?
subjective outcomes; exacerbations requir-
ingOCS, asthma-related SAEs, withdrawal
Yes “double-blind”
Incomplete outcome data addressed? Yes Reasons forwithdrawal not given, although
the numbers of withdrawals were in line
with those in other trials in this review and
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Villa 2002 (Continued)
balanced between treatment arms
Free of selective reporting? Unclear Missing data in study report fromAZ. PEF,
number of inhalations, night-time awaken-
ings, days restricted activity, FEV1, quality
of life, adverse events, ECG, blood pressure
Free of other bias? No Publication bias. Just study report and 2
conference abstracts. No full paper
ATS: American Thoracic Society; ECG: electrocardiogram; ER/ED: emergency room/emergency department; FEV1: forced expiratory
volume in one second; GINA: Global Initiative for Asthma; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICS:
inhaled corticosteroid; LABA: long-acting beta2-agonist; OCS: oral corticosteroid; PEF: peak expiratory flow; SABA: short-acting
beta2-agonist; SAE: serious adverse event
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bisgaard 2005 STAY trial; budesonide/formoterol in a single inhaler as maintenance and reliever compared to same dose single
inhaler as maintenance and terbutaline as reliever
Boskovska 2001 Formoterol twice daily versus salbutamol as-needed
Cheung 2006 Cross-over
Kesten 1991 Randomised to formoterol or albuterol twice daily plus albuterol as-needed
O’Connor 2000 Cross-over
Richter 2007 Formoterol as maintenance versus formoterol as-needed
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D A T A A N D A N A L Y S E S
Comparison 1. Formoterol versus short-acting beta2-agonist
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with an exacerbation
requiring hospitalisation
7 22236 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.67, 1.04]
2 Patients with an exacerbation
requiring a course of oral
corticosteroids
6 21591 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.77, 0.91]
3 Fatal serious adverse events
(all-cause)
5 21629 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.51, 2.30]
4 Patients with a serious adverse
event (all-cause)
7 22538 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.81, 1.08]
5 Patients with a serious adverse
event (asthma-related)
6 21986 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.72, 1.15]
6 Peak expiratory flow (morning) 4 Mean Difference (Fixed, 95% CI) 3.88 [1.29, 6.46]
7 Peak expiratory flow (evening) 4 Mean Difference (Fixed, 95% CI) 2.05 [-0.50, 4.60]
8 Fixed expiratory flow in one
second (FEV1) litres
1 Mean Difference (Fixed, 95% CI) Totals not selected
9 Change in FEV1 % predicted 3 Mean Difference (Fixed, 95% CI) 0.61 [-0.49, 1.71]
10 Withdrawals (any reason) 7 22541 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [1.02, 1.24]
Comparison 2. Formoterol versus short-acting beta2-agonist (background ICS use)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with an exacerbation
requiring a course of oral
corticosteroids
4 3669 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.78 [0.65, 0.94]
1.1 Maintenance ICS 3 2994 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.62, 0.91]
1.2 No maintenance ICS 1 675 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [0.70, 3.10]
2 Patients with a serious adverse
event (all-cause)
7 22538 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.81, 1.08]
2.1 Maintenance ICS 6 17785 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.78, 1.06]
2.2 No maintenance ICS 2 4753 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.77, 1.69]
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Comparison 3. Formoterol versus short-acting beta2-agonists (background LABA use)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with a serious adverse
event (all-cause)
6 21863 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.81, 1.09]
1.1 Maintenance LABA 3 8319 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.68, 1.03]
1.2 No maintenance LABA 4 13544 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.86, 1.30]
Analysis 1.1. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 1 Patients with an
exacerbation requiring hospitalisation.
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 1 Patients with an exacerbation requiring hospitalisation
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ind 2002 3/176 0/181 0.3 % 7.32 [ 0.38, 142.80 ]
Jain 2004 2/29 5/31 2.6 % 0.39 [ 0.07, 2.16 ]
Rabe 2006 23/1137 26/1138 14.5 % 0.88 [ 0.50, 1.56 ]
RELIEF 2003 111/8924 134/8938 75.4 % 0.83 [ 0.64, 1.07 ]
SD-037-0714 2/228 4/227 2.3 % 0.49 [ 0.09, 2.72 ]
SD-037-0716 1/333 2/342 1.1 % 0.51 [ 0.05, 5.67 ]
Villa 2002 7/277 7/275 3.9 % 0.99 [ 0.34, 2.87 ]
Total (95% CI) 11104 11132 100.0 % 0.84 [ 0.67, 1.04 ]
Total events: 149 (Formoterol), 178 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 3.49, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
0.02 0.1 1 10 50
Favours formoterol Favours SABA
39Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 2 Patients with an
exacerbation requiring a course of oral corticosteroids.
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 2 Patients with an exacerbation requiring a course of oral corticosteroids
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ind 2002 34/176 39/181 2.7 % 0.87 [ 0.52, 1.46 ]
Jain 2004 9/29 13/31 0.8 % 0.62 [ 0.22, 1.80 ]
Rabe 2006 170/1137 216/1138 16.2 % 0.75 [ 0.60, 0.94 ]
RELIEF 2003 830/8924 959/8938 76.8 % 0.85 [ 0.77, 0.94 ]
SD-037-0716 17/333 12/342 1.0 % 1.48 [ 0.70, 3.15 ]
Tattersfield 2001 21/182 31/180 2.4 % 0.63 [ 0.35, 1.14 ]
Total (95% CI) 10781 10810 100.0 % 0.84 [ 0.77, 0.91 ]
Total events: 1081 (Formoterol), 1270 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 4.50, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.07 (P = 0.000047)
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Analysis 1.3. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 3 Fatal serious adverse
events (all-cause).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 3 Fatal serious adverse events (all-cause)
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rabe 2006 1/1137 2/1138 0.50 [ 0.05, 5.52 ]
RELIEF 2003 13/8924 11/8938 1.18 [ 0.53, 2.64 ]
SD-037-0714 0/228 0/227 0.0 [ 0.0, 0.0 ]
SD-037-0716 0/333 0/342 0.0 [ 0.0, 0.0 ]
Tattersfield 2001 0/182 0/180 0.0 [ 0.0, 0.0 ]
Total (95% CI) 10804 10825 1.08 [ 0.51, 2.30 ]
Total events: 14 (Formoterol), 13 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 1.4. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 4 Patients with a
serious adverse event (all-cause).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 4 Patients with a serious adverse event (all-cause)
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ind 2002 7/176 1/181 0.2 % 7.46 [ 0.91, 61.24 ]
Rabe 2006 55/1137 65/1138 16.1 % 0.84 [ 0.58, 1.21 ]
RELIEF 2003 278/8924 299/8938 75.3 % 0.93 [ 0.79, 1.10 ]
SD-037-0714 12/228 13/227 3.2 % 0.91 [ 0.41, 2.05 ]
SD-037-0716 6/333 6/342 1.5 % 1.03 [ 0.33, 3.22 ]
Tattersfield 2001 0/182 3/180 0.9 % 0.14 [ 0.01, 2.71 ]
Villa 2002 15/277 11/275 2.7 % 1.37 [ 0.62, 3.05 ]
Total (95% CI) 11257 11281 100.0 % 0.94 [ 0.81, 1.08 ]
Total events: 373 (Formoterol), 398 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 6.58, df = 6 (P = 0.36); I2 =9%
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 1.5. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 5 Patients with a
serious adverse event (asthma-related).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 5 Patients with a serious adverse event (asthma-related)
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ind 2002 3/176 0/181 7.32 [ 0.38, 142.80 ]
Rabe 2006 23/1137 26/1138 0.88 [ 0.50, 1.56 ]
RELIEF 2003 108/8924 121/8938 0.89 [ 0.69, 1.16 ]
SD-037-0714 3/228 3/227 1.00 [ 0.20, 4.99 ]
SD-037-0716 1/333 2/342 0.51 [ 0.05, 5.67 ]
Tattersfield 2001 0/182 0/180 0.0 [ 0.0, 0.0 ]
Total (95% CI) 10980 11006 0.91 [ 0.72, 1.15 ]
Total events: 138 (Formoterol), 152 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 2.15, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 1.6. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 6 Peak expiratory flow
(morning).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 6 Peak expiratory flow (morning)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Rabe 2006 2.7 (1.66) 63.2 % 2.70 [ -0.55, 5.95 ]
SD-037-0714 6.3 (4.18) 10.0 % 6.30 [ -1.89, 14.49 ]
SD-037-0716 3 (3.14) 17.6 % 3.00 [ -3.15, 9.15 ]
Tattersfield 2001 11 (4.34) 9.2 % 11.00 [ 2.49, 19.51 ]
Total (95% CI) 100.0 % 3.88 [ 1.29, 6.46 ]
Heterogeneity: Chi2 = 3.61, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 7 Peak expiratory flow
(evening).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 7 Peak expiratory flow (evening)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Rabe 2006 0.9 (1.63) 63.7 % 0.90 [ -2.29, 4.09 ]
SD-037-0714 2.8 (4.82) 7.3 % 2.80 [ -6.65, 12.25 ]
SD-037-0716 2 (3.11) 17.5 % 2.00 [ -4.10, 8.10 ]
Tattersfield 2001 8 (3.83) 11.5 % 8.00 [ 0.49, 15.51 ]
Total (95% CI) 100.0 % 2.05 [ -0.50, 4.60 ]
Heterogeneity: Chi2 = 2.94, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 8 Fixed expiratory flow
in one second (FEV1) litres.
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 8 Fixed expiratory flow in one second (FEV1) litres
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Rabe 2006 0.03 (0.015) 0.03 [ 0.00, 0.06 ]
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Analysis 1.9. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 9 Change in FEV1 %
predicted.
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 9 Change in FEV1 % predicted
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
SD-037-0714 1.9 (0.92) 37.2 % 1.90 [ 0.10, 3.70 ]
SD-037-0716 -1.1 (0.77) 53.0 % -1.10 [ -2.61, 0.41 ]
Tattersfield 2001 5 (1.79) 9.8 % 5.00 [ 1.49, 8.51 ]
Total (95% CI) 100.0 % 0.61 [ -0.49, 1.71 ]
Heterogeneity: Chi2 = 12.91, df = 2 (P = 0.002); I2 =85%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Formoterol versus short-acting beta2-agonist, Outcome 10 Withdrawals (any
reason).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 1 Formoterol versus short-acting beta2-agonist
Outcome: 10 Withdrawals (any reason)
Study or subgroup Formoterol
Short-acting
beta-agonist Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ind 2002 28/176 34/181 3.8 % 0.82 [ 0.47, 1.42 ]
Rabe 2006 132/1140 151/1141 18.1 % 0.86 [ 0.67, 1.10 ]
RELIEF 2003 664/8924 525/8938 65.8 % 1.29 [ 1.14, 1.45 ]
SD-037-0714 11/228 20/227 2.6 % 0.52 [ 0.25, 1.12 ]
SD-037-0716 23/333 28/339 3.5 % 0.82 [ 0.46, 1.46 ]
Tattersfield 2001 21/182 32/180 3.9 % 0.60 [ 0.33, 1.09 ]
Villa 2002 17/277 18/275 2.3 % 0.93 [ 0.47, 1.85 ]
Total (95% CI) 11260 11281 100.0 % 1.12 [ 1.02, 1.24 ]
Total events: 896 (Formoterol), 808 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 20.34, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 2.27 (P = 0.023)
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Analysis 2.1. Comparison 2 Formoterol versus short-acting beta2-agonist (background ICS use), Outcome
1 Patients with an exacerbation requiring a course of oral corticosteroids.
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 2 Formoterol versus short-acting beta2-agonist (background ICS use)
Outcome: 1 Patients with an exacerbation requiring a course of oral corticosteroids
Study or subgroup Formoterol
Short-acting
beta-agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Maintenance ICS
Ind 2002 34/176 39/181 12.9 % 0.87 [ 0.52, 1.46 ]
Rabe 2006 170/1137 216/1138 71.0 % 0.75 [ 0.60, 0.94 ]
Tattersfield 2001 21/182 31/180 9.9 % 0.63 [ 0.35, 1.13 ]
Subtotal (95% CI) 1495 1499 93.8 % 0.75 [ 0.62, 0.91 ]
Total events: 225 (Formoterol), 286 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
2 No maintenance ICS
SD-037-0716 17/333 12/342 6.2 % 1.47 [ 0.70, 3.10 ]
Subtotal (95% CI) 333 342 6.2 % 1.47 [ 0.70, 3.10 ]
Total events: 17 (Formoterol), 12 (Short-acting beta-agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 1828 1841 100.0 % 0.78 [ 0.65, 0.94 ]
Total events: 242 (Formoterol), 298 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.58 (P = 0.010)
Test for subgroup differences: Chi2 = 2.94, df = 1 (P = 0.09), I2 =66%
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Analysis 2.2. Comparison 2 Formoterol versus short-acting beta2-agonist (background ICS use), Outcome
2 Patients with a serious adverse event (all-cause).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 2 Formoterol versus short-acting beta2-agonist (background ICS use)
Outcome: 2 Patients with a serious adverse event (all-cause)
Study or subgroup Formoterol
Short-acting
beta-agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Maintenance ICS
Ind 2002 7/176 1/181 1.1 % 4.75 [ 1.17, 19.28 ]
Rabe 2006 55/1137 65/1138 15.3 % 0.84 [ 0.58, 1.21 ]
RELIEF 2003 229/6877 257/6907 63.1 % 0.89 [ 0.74, 1.07 ]
SD-037-0714 12/228 13/227 3.2 % 0.91 [ 0.41, 2.05 ]
Tattersfield 2001 0/182 3/180 0.4 % 0.13 [ 0.01, 1.28 ]
Villa 2002 15/277 11/275 3.3 % 1.37 [ 0.62, 3.01 ]
Subtotal (95% CI) 8877 8908 86.4 % 0.91 [ 0.78, 1.06 ]
Total events: 318 (Formoterol), 350 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 9.40, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 1.22 (P = 0.22)
2 No maintenance ICS
RELIEF 2003 49/2047 42/2031 12.0 % 1.16 [ 0.77, 1.76 ]
SD-037-0716 6/333 6/342 1.6 % 1.03 [ 0.33, 3.22 ]
Subtotal (95% CI) 2380 2373 13.6 % 1.14 [ 0.77, 1.69 ]
Total events: 55 (Formoterol), 48 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 11257 11281 100.0 % 0.94 [ 0.81, 1.08 ]
Total events: 373 (Formoterol), 398 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 10.61, df = 7 (P = 0.16); I2 =34%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =14%
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Analysis 3.1. Comparison 3 Formoterol versus short-acting beta2-agonists (background LABA use),
Outcome 1 Patients with a serious adverse event (all-cause).
Review: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Comparison: 3 Formoterol versus short-acting beta2-agonists (background LABA use)
Outcome: 1 Patients with a serious adverse event (all-cause)
Study or subgroup Formoterol
Short-acting
beta-agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Maintenance LABA
Ind 2002 7/176 1/181 1.1 % 4.75 [ 1.17, 19.28 ]
Rabe 2006 55/1137 65/1138 15.6 % 0.84 [ 0.58, 1.21 ]
RELIEF 2003 111/2782 145/2905 33.5 % 0.79 [ 0.62, 1.02 ]
Subtotal (95% CI) 4095 4224 50.1 % 0.84 [ 0.68, 1.03 ]
Total events: 173 (Formoterol), 211 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 6.10, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.69 (P = 0.091)
2 No maintenance LABA
RELIEF 2003 167/6142 154/6033 42.8 % 1.07 [ 0.85, 1.33 ]
SD-037-0714 12/228 13/227 3.2 % 0.91 [ 0.41, 2.05 ]
Tattersfield 2001 0/182 3/180 0.4 % 0.13 [ 0.01, 1.28 ]
Villa 2002 15/277 11/275 3.4 % 1.37 [ 0.62, 3.01 ]
Subtotal (95% CI) 6829 6715 49.9 % 1.06 [ 0.86, 1.30 ]
Total events: 194 (Formoterol), 181 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 3.77, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 10924 10939 100.0 % 0.94 [ 0.81, 1.09 ]
Total events: 367 (Formoterol), 392 (Short-acting beta-agonist)
Heterogeneity: Chi2 = 12.31, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
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Table 1. Randomised as-needed medication and maintenance therapies
Study ID Intervention as-needed medica-
tion [mean daily puffs (range)]
Control medication as-needed
[mean daily puffs (range)]
Maintenance medication [mean
daily ICS dose]
Ind 2002 Formoterol, 4.5 µg DPI
[2.16 (0.00 to 6.3)]
Terbutaline, 0.5 mg DPI
[2.34 (0.1 to 7.5)]
All on formoterol , 9 µg DPI, twice
a day and maintenance inhaled or
oral corticosteroids
Jain 2004 Formoterol, 4.5 µg DPI Salbutamol, 100 µg DPI Not stated
Rabe 2006 Formoterol, 4.5 µg DPI
[1.9 (0.0 to 9.1)]
Terbutaline, 0.4 mg DPI
[1.9 (0.3 to 9.7)]
Budesonide/formoterol, 160/4.5µg
DPI combined inhaler
RELIEF 2003 Formoterol, 4.5 µg DPI Salbutamol, 200 µg DPI (6 coun-
tries) or PMDI (18 countries)
Any ordinary asthma medication
apart from other relief medication,
changes in maintenance medication
allowed [76% participants on 760
µg]
SD-037-0714 Formoterol, 4.5 µg DPI Terbutaline, 0.5 mg DPI All on inhaled corticosteroids ([380
µg] 200 to 500 µg per day), but not
long-acting beta2-agonists
SD-037-0716 Formoterol, 4.5 µg DPI Terbutaline, 0.5 mg DPI Not inhaled corticosteroids or other
anti-inflammatories
Tattersfield 2001 Formoterol, 4.5 µg DPI
[3.92]
Terbutaline, 0.5 mg DPI
[4.89]
All on inhaled corticosteroids [875
µg]. No beta2-agonists allowed but
other asthma medications at con-
stant dosage permitted
Villa 2002 Formoterol, 4.5 µg DPI Terbutaline, 0.25 mg DPI Inhaled
corticosteroids [410 µg], disodium
cromoglycate or nedocromil
DPI ; Dry power inhaler; PMDI: pressurised metered dose inhaler.
Table 2. Study characteristics
Study ID Number of par-
ticipants
Duration Mean age (range) Locale centres
(countries)
Asthma severity Sponsor
Ind 2002 375 12 weeks 47 42 (5) stable on ICS AZ
Jain 2004 60 6 months ? ? ? ?
Rabe 2006 2281 12 months 42 (12 to 81) 289 (20) moderate to severe AZ
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Table 2. Study characteristics (Continued)
RELIEF 2003 17,862 6 months 39 (4 to 91) 1139 (24) intermittent,
mild, moderate or
severe
AZ
SD-037-0714 455 12 months 25 (6 to 75) 48 (4) mild AZ
SD-037-0716 675 12 months 24 (6 to 87) 54 (8) intermittent AZ
Tattersfield 2001 362 12 weeks 47 (18 to 75) 35 (4) mild to moderate AZ
Villa 2002 552 6 months 11 (5 to 19) 77 (9) mild or moderate
persistent
AZ
Table 3. Withdrawals
Study ID Eligibility criteria Discontinuations due
to adverse events
Lost to follow up Total numbers of
withdrawals
N
For-
moterol
SABA For-
moterol
SABA For-
moterol
SABA For-
moterol
SABA For-
moterol
SABA
Ind 2002 8 9 14 14 1 8 28 (15.
9%)
34 (18.
8%)
176 181
Rabe
2006
50 56 22 (1.9%) 19 (1.6%) 14 (1.2%) 9 (1.6%) 132 (11.
5%)
151
(13%)
1140 1141
RELIEF
2003
12 21 213 (2.
4%)
119 (1.
3%)
221 (2.
5%)
204 (3.
2%)
664 (7.
4%)
525 (5.
9%)
8924 8938
SD-037-
0714
2 3 2 3 - - 11 (4.8%) 20 (8.8%) 228 227
SD-037-
0716
- - 0 2 - - 23 (6.9%) 28 (8.3%) 333 339
Tatters-
field
2001
- - 8 18 - - 21 (6.3%) 32 (17.
8%)
182 180
Villa
2002
- - 3% 3% - - 17 (7.5%) 18 (6.5%) 227 275
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H I S T O R Y
Protocol first published: Issue 3, 2010
Review first published: Issue 9, 2010
C O N T R I B U T I O N S O F A U T H O R S
EJW extracted information for the characteristics of included studies and CJC checked them. CJC and EJW independently extracted
the data and entered data into RevMan. EJW drafted the review with input from CJC.
CJC and EJW co-authored the protocol.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR, UK.
Funding for research time for CJC and EW
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not perform subgroup analyses on the basis of age or asthma severity.
We did not ask trialists for separate data for adults and children.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Age Factors; Albuterol [therapeutic use]; Asthma [∗drug therapy]; Bronchodilator Agents [∗therapeutic use]; Budesonide [therapeutic
use]; Cromolyn Sodium [therapeutic use]; Ethanolamines [∗therapeutic use]; Nedocromil [therapeutic use]; Randomized Controlled
Trials as Topic; Terbutaline [therapeutic use]
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MeSH check words
Adult; Child; Humans
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